Topics:

Trials of AccuSite Injectable Gel From Matrix Begin in Basal Cell Ca

Trials of AccuSite Injectable Gel From Matrix Begin in Basal Cell Ca

MENLO PARK, Calif--Matrix Pharmaceutical, Inc. has initiated two phase III trials of its AccuSite injectable gel for patients with basal cell cancer. The company has completed phase III testing of the gel for the treatment of genital warts and expects to submit a new drug application to the FDA for that indication later this year.

One of the basal cell cancer trials is an open-label long-term safety and efficacy study expected to enroll approximately 400 patients from 20 to 25 sites in Europe, Australia, New Zealand, and the United States. The second trial is a placebo-controlled study involving 225 patients, designed to provide histologic confirmation of clinical response.

 
Loading comments...
Please Wait 20 seconds or click here to close